<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2720">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779879</url>
  </required_header>
  <id_info>
    <org_study_id>VIR-7831-5006</org_study_id>
    <secondary_id>GSK Study 216912</secondary_id>
    <nct_id>NCT04779879</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19</brief_title>
  <acronym>COMET-PEAK</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Participants With Mild to Moderate Coronavirus Disease 2019 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vir Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vir Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will&#xD;
      receive VIR-7831 (Gen1) or VIR-7831 (Gen2) and will be assessed for safety, tolerability, and&#xD;
      pharmacokinetics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events (AEs)</measure>
    <time_frame>Through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events (SAEs)</measure>
    <time_frame>Through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events of special interest (AESIs)</measure>
    <time_frame>Through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of clinically significant abnormalities on 12-lead electrocardiogram (ECG) readings</measure>
    <time_frame>Through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of disease progression events (not classified as AEs)</measure>
    <time_frame>Through Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clast</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCD0-28</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCexp</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of SAEs</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of AESIs</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinically significant abnormalities on 12-lead ECG readings</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of disease progression events (not classified as AEs)</measure>
    <time_frame>Through 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>VIR-7831 (Gen1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VIR-7831 (Gen2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VIR-7831 (Gen1)</intervention_name>
    <description>VIR-7831 (Gen1) given as IV infusion</description>
    <arm_group_label>VIR-7831 (Gen1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VIR-7831 (Gen2)</intervention_name>
    <description>VIR-7831 (Gen2) given as IV infusion</description>
    <arm_group_label>VIR-7831 (Gen2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be aged 18 years or older at the time of obtaining informed consent&#xD;
&#xD;
          -  Participants who have a positive SARS-CoV-2 test result ≤7 days prior to enrollment&#xD;
             and oxygen saturation ≥94% on room air and have COVID-19 symptoms and ≤7 days from&#xD;
             onset of symptoms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently hospitalized or judged by the investigator as likely to require&#xD;
             hospitalization in the next 24 hours&#xD;
&#xD;
          -  Symptoms consistent with severe COVID-19&#xD;
&#xD;
          -  Participants who, in the judgement of the investigator are likely to die in the next 7&#xD;
             days.&#xD;
&#xD;
          -  Severely immunocompromised participants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Inquiry</last_name>
    <phone>415-654-5281</phone>
    <email>clinicaltrials@vir.bio</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>coronavirus</keyword>
  <keyword>coronavirus disease 2019</keyword>
  <keyword>COVID-19</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

